Compare
Cumberland Pharmaceuticals Inc vs Lexicon Pharmaceuticals, Inc. vs Lftd Partners Inc. vs Sunshine Biopharma Inc.
| Latest fiscal year | Cumberland Pharmaceuticals Inc CPIX | Lexicon Pharmaceuticals, Inc. LXRX | Lftd Partners Inc. LIFD | Sunshine Biopharma Inc. SBFM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $44.52M | $49.80M | $36.92M | $36.31M |
| Revenue growth (YoY) | +17.6% | +60.2% | -1.1% | +4.1% |
| Gross margin | 85.0% (computed) | n/a | 34.2% | 33.8% |
| Operating margin | -6.3% | -98.2% | 2.5% | -17.2% |
| Net margin | -6.4% | -101.1% | -67.3% | -16.5% |
| Net income | -$2.84M | -$50.34M | -$24.86M | -$5.98M |
| EPS (Diluted) | -$0.19 | -$0.14 | -$1.68 | n/a |
| Operating cash flow | $4.93M | -$67.85M | $1.32M | -$5.33M |
| Free cash flow | $4.83M | -$67.85M | $1.20M | -$5.51M |
| Cash & equivalents | $11.44M | $34.33M | $1.77M | n/a |
| Total assets | $76.82M | $184.99M | $19.27M | $30.08M |
| Total liabilities | $52.28M | $77.45M | $6.64M | $7.04M |
| Shareholders' equity | $24.88M | $107.54M | $12.63M | $23.04M |
| Return on year-end equity | -11.4% | -46.8% | -196.8% | -25.9% |
| Shares outstanding | 14.96M | 365.85M | 14.82M | 4.91M |
Revenue, most recent five fiscal years
| Fiscal year | Cumberland Pharmaceuticals Inc | Lexicon Pharmaceuticals, Inc. | Lftd Partners Inc. | Sunshine Biopharma Inc. |
|---|---|---|---|---|
| Latest | $44.52M Ended 2025-12-31 | $49.80M Ended 2025-12-31 | $36.92M Ended 2025-12-31 | $36.31M Ended 2025-12-31 |
| 1 year earlier | $37.87M Ended 2024-12-31 | $31.08M Ended 2024-12-31 | $37.33M Ended 2024-12-31 | $34.87M Ended 2024-12-31 |
| 2 years earlier | $39.55M Ended 2023-12-31 | $1.20M Ended 2023-12-31 | $51.61M Ended 2023-12-31 | $24.09M Ended 2023-12-31 |
| 3 years earlier | $42.01M Ended 2022-12-31 | $139.0K Ended 2022-12-31 | $57.42M Ended 2022-12-31 | $4.35M Ended 2022-12-31 |
| 4 years earlier | $35.05M Ended 2021-12-31 | $298.0K Ended 2021-12-31 | $31.66M Ended 2021-12-31 | $228.4K Ended 2021-12-31 |